Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis

NCT05511519 is registered in ClinicalTrials.gov with Aclaris Therapeutics, Inc. as lead sponsor.

NCT NCT05511519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05511519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis
Lead sponsor
Aclaris Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 12, 2022
Completion date
January 3, 2024
Enrollment
47 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis